Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02459275 · ClinicalTrials.gov registry record · Phase 4

PEP uP Protocol in Surgical Patients

A Phase 4 study, sponsored by Clinical Evaluation Research Unit at Kingston General Hospital.

Terminated
Registry status
Phase 4
Development phase
36
Enrollment target

NCT02459275: Clinical Trial Phase 4 study, sponsored by Clinical Evaluation Research Unit at Kingston General Hospital.

NCT02459275 is a Phase 4 study that was terminated before completion, run by Clinical Evaluation Research Unit at Kingston General Hospital. The registered enrollment target is 36 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02459275, a Phase 4 study, was terminated before completion, sponsored by Clinical Evaluation Research Unit at Kingston General Hospital.

TERMINATED
Registry status
Phase 4
Development phase
36 participants
Enrollment target

Study Summary

The main objective of this project is to asses for safety, feasibility and effectiveness of an aggressive feeding protocol, PEP uP (Enhanced Protein-Energy Provision via the Enteral Route Feeding Protocol) in increasing protein and energy delivery to critically ill surgical patients. Our hypothesis is that an aggressive feeding protocol, PEP uP will be safe, acceptable, and effectively increase protein and energy delivery to critically ill surgical patients.

Primary Outcome

The total amount of protein received from either EN or parenteral nutrition (PN), inclusive of propofol, divided by the amount prescribed as per the baseline assessment and expressed as a percentage.

Interventions

  • DRUG Metoclopramide
  • OTHER PEP uP Protocol

Trial Details

FieldValue
Enrollment Target 36 participants
Start Date 2015-07
Est. Completion 2017-09
Phase Phase 4

Why NCT02459275 stopped before completion

NCT02459275 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (93% lower).

The record links to 0 conditions, and to 2 interventions - of which Metoclopramide is the first listed.

NCT02459275 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02459275 about?

NCT02459275 is a clinical study titled "PEP uP Protocol in Surgical Patients". The main objective of this project is to asses for safety, feasibility and effectiveness of an aggressive feeding protocol, PEP uP (Enhanced Protein-Energy Provision via the Enteral Route Feeding Protocol) in increasing protein and energy delivery to critically ill surgical patients. Our hypothesis ...

What is the current status of trial NCT02459275?

This trial is currently terminated. It is a Phase 4 study. The enrollment target is 36 participants. The study started on 2015-07. Estimated completion is 2017-09.

What interventions are being tested in trial NCT02459275?

The interventions under investigation include: Metoclopramide (DRUG), PEP uP Protocol (OTHER).

Who is sponsoring clinical trial NCT02459275?

This trial is sponsored by Clinical Evaluation Research Unit at Kingston General Hospital, which has 5 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02459275's enrollment target sits among peer trials

36 1490th of 2000 higher than 495 of 2,000 other Phase 4 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00929006 · 36 participants · Early Phase 1

    Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism

  • NCT01891318 · 36 participants · Phase 1

    Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study

  • NCT02291848 · 36 participants · Phase 1

    Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma

  • NCT02366819 · 36 participants · Phase 4

    Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02459275, the US trial registry maintained by the National Library of Medicine. NCT02459275 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.